Summary
This prediction ended on 22.04.15 with a price of €84,800,000. The BUY prediction by melinda for Neovacs performed very badly with a performance of -67.18%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Neovacs | - | - | - | - |
| iShares Core DAX® | -2,20 % | 0,67 % | 0,55 % | 51,11 % |
| iShares Nasdaq 100 | -2,63 % | 2,99 % | 34,11 % | 91,99 % |
| iShares Nikkei 225® | -2,02 % | 3,14 % | 53,42 % | 65,85 % |
| iShares S&P 500 | -1,67 % | 2,40 % | 23,22 % | 66,64 % |
According to melinda what are the pros and cons of Neovacs for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Neovacs diskutieren
Biotech-
Markt Antikörper
(Laufzeit überschritten)